Search
Now showing items 81-90 of 111
Symptom Dynamics and Attention in Depression: Fatigue and Low Positive Affect are Associated With Reduced Orienting Efficiency
(2022-02)
Depression is a heterogeneous mental disorder involving a complex interplay between
potential etiological and maintenance factors. The current study examined how depression
heterogeneity is related to attentional ...
Inducing Affective Learning Biases with Cognitive Training and Prefrontal tDCS: A Proof-of-Concept Study
(2020-10)
Cognitive models of mood disorders emphasize a causal role of negative affective biases in depression. Computational work suggests that these biases may stem from a belief that negative events have a higher information ...
Pramipexole Enhances Reward Learning by Preserving Value Estimates
(2022-01)
Background: Dopamine D2-like receptor agonists show promise as treatments for depression. They are
thought to act by altering how individuals learn from rewarding experiences. However, the nature of these
reward learning ...
Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: protocol for systematic review and network meta-analysis
(2022-04)
For major depression, a one-size-fits-all treatment does not exist. Patients enter a ‘trial-and-change’ algorithm in which effective therapies are subsequently applied. Unfortunately, an empirically based order of treatments ...
Sleep deprivation as a treatment for major depressive episodes: A systematic review and meta-analysis
(2022-05)
Sleep deprivation, alone or in combination with pharmacological treatment and as part of a chronotherapy package, is of potential use for people with major depressive episodes, however the evidence base is still conflicting. ...
Important adverse events to be evaluated in antidepressant trials and meta-analyses in depression: a large international preference study including patients and healthcare professionals
(2022-07)
Background: Non-serious adverse events (NSAEs) should be captured and reported because they can have a significant negative impact on patients and treatment adherence. However, the reporting of NSAEs in randomised controlled ...
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis
(2022-06)
Background: Brexpiprazole augmentation is an effective treatment strategy for antidepressant-refractory depression, but its optimal dosage remains unclear.
Aims: To find the optimal dosage of brexpiprazole as augmentation ...
Investigating inflammation in depression in the chronically ill: Theoretical model and perspectives
(2022-07)
Inflammation is a risk factor for chronic physical illnesses. Evidence is building that inflammation is also a risk factor for mental illnesses making inflammation a common mechanism which could explain the high comorbidity ...
Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment
(2021-10)
Background: Clinical trials with putative antidepressants can be difficult to execute as it can take up to 8 weeks before differences emerge between drug and placebo, and long expensive trials often fail. Implementation ...
No Association Between Amygdala Responses to Negative Faces and Depressive Symptoms: Cross-Sectional Data from 28,638 Individuals in the UK Biobank Cohort
(2022-07)
In this Priority Data Letter, we report on the largest study to date to test the association between amygdala reactivity and depressive symptoms based on UK Biobank data. For transparency, we initially set out to investigate ...